Human MUC1 mucin, a membrane-bound glycoprotein, is a major component of the ductal cell surface of normal glandular cells. MUC1 is overexpressed and aberrantly glycosylated in carcinoma cells. The role MUC1 plays in cancer progression represents two sides of one coin.
Breast cancer is traumatic not only for the women who develop it, but also for the men in their lives. I know. In 1991, my wife was diagnosed, and I found myself along for an unpleasant ride as she had surgery, two months of daily radiation, and six months of biweekly chemotherapy, not to mention the emotional upheaval the disease engenders.
The recognition and description of tumor growth control factors, together with the development of interventions that modulate their biologic activity, represent a major focus for current cancer research, which already has changed the practice of clinical oncology.
Three Weeks of Two-Drug Chemotherapy as Good as Six Weeks of Triple Chemotherapy
In a study published today in Europe's leading reproductive medicine journal Human Reproduction1, researchers from New York's Cornell University report the first IVF pregnancy to result from the use of tamoxifen as an ovarian stimulant.
Research published in this week's issue of Nature describes the molecular structure of two cancer-related proteins binding to one another. Scientists identified the biochemical and signaling properties of these molecules using a process called X-ray crystallography.
Talk about breast cancer and naturally, people think of the disease that is the number one cancer among women. But the truth is that breast cancer is on the rise among both women and men, and researchers think the national obesity crisis may be to blame.
Gene expression profiling has been successfully used to classify breast cancer into clinically distinct subtypes, and to predict the risk of recurrence and treatment response. The aim of this study was to investigate whether the gene expression profile (GEP) detected in a core biopsy (CB) is representative for the entire tumor, since CB is an important tool in breast cancer diagnosis.
It has been suggested that hormonal risk factors act predominantly on estrogen receptor and progesterone receptor (ER/PR)-positive breast cancers. However, the data have been inconsistent, especially in younger women.
Most previous studies have focused on evaluating the association between circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and breast cancer risk. Emerging evidence over the past few years suggests that IGFBP-3 may act directly on mammary epithelial cells.